MED12 and prostate carcinoma: MED12L/MED12 amplification is enriched in BRCA2‐mutant prostate cancer with IDC‐P, particularly in cases associated with a poor prognosis. MYC amplifications is enriched in BRCA2‐mutant prostate cancer with IDC‐P.